Crestline Management LP Invests $298,000 in Masimo Co. (NASDAQ:MASI)

Crestline Management LP bought a new stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,800 shares of the medical equipment provider's stock, valued at approximately $298,000.

A number of other hedge funds have also made changes to their positions in MASI. Barclays PLC raised its holdings in shares of Masimo by 152.6% during the third quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock valued at $5,329,000 after acquiring an additional 24,137 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of Masimo during the third quarter valued at approximately $319,000. GAMMA Investing LLC raised its holdings in shares of Masimo by 136.5% during the fourth quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider's stock valued at $77,000 after acquiring an additional 269 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Masimo by 0.7% in the fourth quarter. Nordea Investment Management AB now owns 19,182 shares of the medical equipment provider's stock valued at $3,206,000 after purchasing an additional 142 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC acquired a new stake in shares of Masimo in the fourth quarter valued at approximately $241,000. Institutional investors and hedge funds own 85.96% of the company's stock.

Insider Activity at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This represents a 55.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,053 shares of company stock valued at $6,998,565 over the last three months. 9.70% of the stock is owned by corporate insiders.

Masimo Stock Up 0.4%

NASDAQ:MASI traded up $0.63 during midday trading on Friday, reaching $155.02. The company had a trading volume of 160,195 shares, compared to its average volume of 657,562. The stock's fifty day simple moving average is $160.28 and its 200-day simple moving average is $167.06. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $8.40 billion, a price-to-earnings ratio of 106.91 and a beta of 1.23. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.12. The business had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business's quarterly revenue was down 24.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 EPS. On average, sell-side analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Raymond James cut their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company cut their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating and issued a $200.00 price objective (down from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Finally, BTIG Research set a $193.00 price objective on Masimo and gave the stock a "buy" rating in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $191.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.